Shanghai Junshi Biosciences and its subsidiary TopAlliance Biosciences are set to enter a collaboration with LEO Pharma to ...

China’s Junshi Biosciences (HKEX: 1877) yesterday revealed that its wholly-owned subsidiary TopAlliance Bioscience has ...

Leo Pharma has stepped up to commercialize toripalimab in Europe, inking a deal with Shanghai Junshi Biosciences to secure ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

LEO Pharma will be gaining the rights to commercialise Junshi Biosciences’ toripalimab in Europe under a new distribution and ...

Under the agreement, LEO Pharma will be responsible for toripalimab's distribution, promotion, sales, etc., in up to 32 ...

Shanghai-based Junshi Biosciences has announced a partnership with Denmark’s LEO Pharma to distribute and commercialise the ...

Shanghai Junshi Biosciences and its subsidiary TopAlliance Biosciences are set to enter a collaboration with LEO Pharma to distribute and market the monoclonal antibody, toripalimab, in Europe.

Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of LEO Pharma’s Preclinical Oral STAT6 Program, Including Targeted Protein Degraders -- -- Gilead ...

Last Friday saw the USA’s Center for Medicare and Medicaid Services (CMS) announce the selection of 15 new drugs covered ...

Junshi Biosciences enters distribution and marketing partnership with LEO Pharma for toripalimab in Europe: Shanghai, China Wednesday, January 22, 2025, 14:00 Hrs [IST] Shanghai J ...